Category: News

First patient enrolled in the QUEST I clinical study

The Swiss coronary stent company Qvanteq AG enrolled first patient in the QUEST I clinical study

Qvanteq AG today announced that it has enrolled the first patient in the First in Man (FiM) clinical study QUEST I, this is following earlier regulatory approval from the Dutch and Swiss authorities. The aim of the QUEST I study is to assess feasibility and safety of the Qstent, a bioactive, coating-free coronary stent. The Qstent has shown excellent in-growth and low thrombogenicity in pre-clinical studies. Continue reading